Loss of ancestral N-glycosylation sites in conserved proteins during human evolution

DONG SEON KIM, DONGJIN CHOI and YOONSOO HAHN

Department of Life Science, Research Center for Biomolecules and Biosystems, Chung-Ang University, Seoul 156-756, Republic of Korea

Received June 25, 2015; Accepted October 1, 2015

DOI: 10.3892/ijmm.2015.2362

Abstract. N-linked protein glycosylation is involved in various biological processes, such as protein quality control and adhesion or signaling among cells. The loss of ancestrally conserved N-glycosylation sites may result in the evolution of protein structure and function. In the present study, a mouse glycoproteome dataset and mammalian proteome data were assessed to identify 40 ancestral N-glycosylation sites in 37 proteins that disappeared during human evolution since the last common ancestor of the Euarchonta (primates and treeshrews). The results showed that each of the human proteins, CELSR1, ST3GAL5 and VSIG10, lost an ancestrally conserved N-glycosylation site following human-chimpanzee divergence. Notably, CELSR1 and ST3GAL5 are crucial for normal development and function of the mammalian nervous system, suggesting an association with the evolution of human cognitive function. Thus, the lost ancestrally conserved N-glycosylation sites identified in the present study may be useful targets for functional analyses to identify molecular changes linked with the evolution of human phenotypes.

Introduction

N-linked glycosylation is a well-studied protein post-translational modification (PTM) that occurs at the Asn residue in the consensus motif Asn-X-Ser/Thr, where X is any amino acid except Pro (1). N-glycosylation modulates the folding, stability, trafficking and turnover of proteins, especially those of secreted or membrane attached proteins, which are involved in various cell processes such as cell-cell interaction or intracellular signaling (2-4). As N-glycosylation is involved in important cell functions, numerous N-glycosylation sites are evolutionarily conserved (5).

Correspondence to: Professor Yoonsoo Hahn, Department of Life Science, Research Center for Biomolecules and Biosystems, Chung-Ang University, 84 Heukseok-ro Dongjak-gu, Seoul 156-756, Republic of Korea

E-mail: hahny@cau.ac.kr

Key words: evolution, glycoproteome, human, loss, N-glycosylation

We hypothesized that the losses of certain ancestrally conserved N-glycosylation sites during evolution may have been involved in the acquisition of novel human phenotypes. The loss of N-glycosylation often disrupts the normal function of proteins due to improper folding, trafficking, or activity of the proteins (6,7). A proteome-wide analysis of non-synonymous single-nucleotide variations in the N-glycosylation motifs of human proteins revealed that 259 sites were lost because of missense substitutions, some of which are involved in various diseases (8). Although loss of a glycosylation modification usually results in disadvantageous phenotypes, some losses may be beneficial and fixed in humans during evolution. For example, loss of the glycan moiety N-glycolylneuraminic acid from cell surface proteins by the inactivation of the CMAH gene, encoding CMP-Nacetylneuraminic acid hydroxylase, was associated with the evolution of resistance to a certain type of malaria in early humans, although this loss subsequently led to susceptibility to other pathogens (9,10).

A large number of N-glycosylation sites identified from non-human animals and a suitable bioinformatics procedure are necessary to identify cases where ancestrally conserved N-glycosylation sites were lost during human evolution. An ideal dataset for this analysis is the N-glycoproteome data obtained from mouse tissues and plasma using high-throughput mass spectrometry (11). Previously, a bioinformatics method was used to identify novel gains of N-glycosylation sites during human evolution (12). In the present study, the procedure involved a simple modification to identify losses of ancestral N-glycosylated Asn residues during human evolution following the divergence of the Euarchonta lineage from the Glires lineage. Additionally, a comprehensive literature survey was performed to infer the possible functional outcomes of these changes, especially for human-specific losses.

Materials and methods

Mouse N-glycosylation site data. For the N-linked glycosylation dataset from a non-human proteome, we initially tested mouse data in the UniProt database. However, there were only 419 experimentally verified mouse N-glycosylation sites (as of December 20, 2013). Therefore, mouse N-glycoproteome dataset from Zielinska *et al* was utilized (11). This dataset consisted of 6,367 N-linked glycosylation sites in

2,352 proteins. Approximately 74% of the sites in the UniProt database were re-identified in this data set.

Mammalian orthologous proteins. Mammalian orthologs of the mouse glycosylated proteins were obtained from the University of California Santa Cruz (UCSC) Genome Browser Database (http://genome.ucsc.edu). The 'CDS FASTA alignment from multiple alignments' data, derived from the 'multiz100way' alignment data prepared from 100 vertebrate genomes (13), were downloaded using the Table Browser tool of the UCSC Genome Browser (14). Orthologous protein sequences from 62 mammalian species were extracted from these alignment datasets. The selected mammalian species included humans, chimpanzees, gorillas, orangutans, gibbons, rhesus macaques, crab-eating macaques, baboons, green monkeys, marmosets, squirrel monkeys, bushbabies, treeshrews, lesser Egyptian jerboas, prairie voles, Chinese hamsters, golden hamsters, mice, rats, naked mole rats, guinea pigs, chinchillas, brush-tailed rats, rabbits, pikas, pigs, alpacas, Bactrian camels, dolphins, killer whales, Tibetan antelopes, cattle such as cows, sheep, and goats, horses, white rhinoceroses, cats, dogs, ferrets, pandas, Pacific walruses, Weddell seals, black flying foxes, megabats, David's myotis bats, microbats, big brown bats, hedgehogs, shrews, star-nosed moles, elephants, cape elephant shrews, manatees, cape golden moles, tenrecs, aardvarks, armadillos, opossums, Tasmanian devils, wallabies and platypuses. Detailed information on species and genome assemblies is available at the UCSC Genome Browser web site (http://hgdownload.cse.ucsc. edu/goldenPath/hg19/multiz100way).

Computational screening for candidate lost N-glycosylation sites. The total number of mouse N-glycosylation sites in the data set from Zielinska et al was 6,367 (11). The 'multiz100way' alignment data, containing 57,289 alignment sets, were analyzed to identify human and other mammalian orthologs of each of the mouse N-glycosylated proteins (Fig. 1). Ad hoc Perl scripts were used to analyze the data. There were 1,658 orthologous protein datasets containing human and mouse protein sequences. This dataset covered 4,633 mouse N-glycosylation sites. From each dataset, the mammalian sequences were extracted and realigned using MUSCLE (http://www.drive5.com/muscle) (15).

Each of the positions that aligned with a mouse N-glycosylation site was examined using ad hoc Perl scripts. Sites that were conserved in humans, where the human protein had a consensus N-glycosylation motif, were discarded. Sites where ≥30% non-Euarchonta mammals did not have an Asn residue, indicating a frequent loss in these species, were also discarded. A total of 47 sites in 43 protein alignments were obtained after this computational screening step.

Manual inspection to select lost N-glycosylated Asn residues in the human lineage. As a final step, we manually scrutinized the 47 candidates to identify highly probable instances of N-glycosylation site loss during evolution of the human lineage. In each dataset, the species that had many gaps compared to other mammals were removed. When the mouse sequence utilized from Zielinska et al (11) differed from that of the UCSC database by at least three residues, the case was discarded as the orthology of the aligned proteins could not be guaranteed. We also discarded cases in which the mouse N-glycosylation site




Figure 1. Summary of procedure for identifying loss of ancestral N-glycosylation sites during human evolution. Computational screening and manual inspection were employed to identify the loss of ancestral N-glycosylation sites in human proteins during human evolution.

did not conform to the canonical sequence, or cases showing low sequence conservation among mammals.

Finally, 40 ancestral N-glycosylation sites in 37 proteins were identified to be lost during human evolution. The human and mouse protein sequences in the UCSC alignment were mapped to UniProt database sequences to utilize the UniProt annotation record. We examined the multiple sequence alignment and the mammalian phylogenetic tree to infer the timing of the loss of the N-glycosylated Asn residue.

Results and Discussion

Identification of N-glycosylation sites lost during human evolution and timing of loss. We applied a bioinformatics procedure previously developed to identify novel N-glycosylation sites during human evolution, with modifications (12). Initially, there were 6,367 experimentally identified mouse N-glycosylation sites from 2,352 proteins in the dataset from Zielinska et al (11) and 57,289 orthologous protein sequence alignments from 62 mammalian species extracted from the UCSC 'multiz100way' data (13,14). These data were analyzed to collect N-glycosylation sites lost during human evolution after the Euarchonta (primates and treeshrews) diverged from the Glires (rodents and rabbits).

As a result, 40 N-glycosylation sites in 37 proteins were identified to have been lost during human evolution (Table I). Of the 37 proteins, three proteins encoded by the *ICAMI*, *LRP2* and *MASP2* genes had each lost two N-glycosylation sites (nos. 13 and 14 for *ICAMI*, 23 and 24 for *LRP2*, and 27 and 28 for *MASP2*), and the remaining 34 proteins had lost one site each. Fig. 2 shows the number of N-glycosylation

Table I. List of ancestral N-glycosylation sites that were lost during human evolution.

| No. | UniProt ID | Position | Sequence ^a | Clade | Gene | Protein |
|-----|----------------------------|------------|---|-----------------------|----------|---|
| 1 | ABCA1_HUMAN ABCA1_MOUSE | 1499 | LPPPQRKQNTADILQDLTGRNISDYLVKTYV LPPPQRKQKTADILQ NLT GRNISDYLVKTYV | Simians | ABCAI | ATP-binding cassette sub-family A member 1 |
| 2 | ADAM9_HUMAN ADAM9_MOUSE | 636 | TKCGAGKICRNFQCVDASVLNYDCDVQKKCH TKCDAGKICRNFQCV NAS VLNYDCDIQGKCH | Primates | ADAM9 | Disintegrin and metalloproteinase domain-containing protein 9 |
| 8 | ASM3A_HUMAN ASM3A_MOUSE | 367 | QYYLNLTEANLKGESIWKLEYILTQTYDIED QYYLNLTEANLKGES NWT LEYVLTQAYSVAD | Simians | SMPDL3A | Acid sphingomyelinase-like phosphodiesterase 3a |
| 4 | C4BPA_HUMAN C4BPA_MOUSE | 67 74 | PPTLSFAAPM-DITLTETRFKTGTTLKYTCL PPAIPNALPA-DV NRT DFESHTTLKYECL | Simians | C4BPA | C4b-binding protein $lpha$ chain |
| S | CAD13_HUMAN CAD13_MOUSE | 489 | GPVFY PDPMMVTRQEDLSVGSVLLTVNATDP GPVFY PDPMMVTKQE NIS VGSVLLTVNATDP | African great apes | СДНІЗ | Cadherin-13 |
| 9 | CBG_HUMAN CBG_MOUSE | 224 217 | QPFDLASTREENFYVDETTVVKVPMMLQSST LPFSPENTREEDFYV NET STVKVPMMVQSGN | Simians | SERPINA6 | Corticosteroid-binding globulin |
| 7 | CELR1_HUMAN CELR1_MOUSE | 2140 | QVDGARALQLVRALRSATQHTGTLFGNDVRT RMDGNRSLRLAKALR NAT QGNSTLFGNDVRT | Humans | CELSRI | Cadherin EGF LAG seven-pass G-type receptor 1 |
| ∞ | CPN2_HUMAN CPN2_MOUSE | 311 | LTHNQLETVAEGTFAHLSNLRSLMLSYNAIT LSYNQLETIPEGAFT NLS RLVSLTLSHNAIT | Primates | CPN2 | Carboxypeptidase N subunit 2 |
| 6 | CSF1R_HUMAN CSF1R_MOUSE | 493 491 | EHNQTYECRAHNSVGSGSWAFIPISAGAHTH KHNMTYFCKTHNSVG NSS QYFRAVSLGQSKQ | Simians | CSFIR | Macrophage colony-stimulating factor 1 receptor |
| 10 | CTL4_HUMAN CTL4_MOUSE | 198 | TNVTPPALPGITNDTTIQQGISGLIDSLN PNITLPEDLRI-N NTT VSNGISGLLDSIN | Euarchonta | SLC44A4 | Choline transporter-like protein 4 |
| 11 | DCC_HUMAN DCC_MOUSE | 09 | EPSDAVTMRGGNVLLDCSAESDRGVPVIKWK EPSDAVTMRGGNVLL NCS AESDRGVPVIKWK | Primates | DCC | Netrin receptor DCC |
| 12 | FETUA_HUMAN FETUA_MOUSE | 66 | TLETTCHVLDPTPVARCSVRQLKEHAVEGDC TLETTCHALDPTPLA NCS VRQLTEHAVEGDC | Catarrhines | AHSG | α -2-HS-glycoprotein |
| 13 | ICAM1_HUMAN ICAM1_MOUSE | 359 | GVPAQPLGPRAQLLLKATPEDNGRSFSCSAT GVEPRPPTPQVQFTL NAS SEDHKRSFFCSAA | Simians | ICAMI | Intercellular adhesion molecule 1 |
| 41 | ICAM1_HUMAN ICAM1_MOUSE | 47 | SPSKVILPRGGSVLVTCSTSCDQPKLLGIET HPREAFLPQGGSVQV NCS SSCKEDLSLGLET | African great apes | ICAMI | Intercellular adhesion molecule 1 |
| 15 | IGSF5_HUMAN IGSF5_MOUSE | 160 | FIPSVNLVVAENEPCEVTCLPSHWTRLPDIS NIPSNNLIVTEGEPC NVT CYAVGWTSLPDIS | Simians | IGSF5 | Immunoglobulin superfamily member 5 |

Table I. Condinued.

| Protein | Integrin β-5 | Laminin subunit α -1 | Laminin subunit α -2 | Lysosome-associated membrane glycoprotein 5 | Large neutral amino acids transporter small subunit 3 | Leucyl-cystinyl aminopeptidase | Lipid phosphate phosphohydrolase 2 | Low-density lipoprotein receptor-related protein 2 | Low-density lipoprotein receptor-related protein 2 | L-selectin | Lysosomal α-mannosidase | Mannan-binding lectin serine protease 2 | Mannan-binding lectin serine protease 2 | Tyrosine-protein kinase Mer | Hepatocyte growth factor receptor |
|-----------------------|---|---|---|---|---|---|---|---|--|---|---|---|---|---|---|
| Gene | IIGB5 | LAMAI | LAMA2 | LAMP5 | SLC43A1 | LNPEP | PPAP2C | LRP2 | LRP2 | SELL | MAN2BI | MASP2 | MASP2 | MERTK | MET |
| Clade | Simians | Simians | Great apes | Simians | African great apes | Humans and chimpanzees | Simians | Catarrhines | Simians | African great apes | Simians | African great apes | Apes | Simians | Simians |
| Sequence ^a | GCSVGLEPNSARCNGSGTYVCGLCECSPGYL GCSTGL-PNSARCSG NGT YTCGLCECDPGYL | IKASYGQGLQQSRISDISMEVGRKAEKLHPE IKASYGQGLQQSRIA NIS MEVGRKAVELPAE | DAVDAKNCQPCRCNAGGSFSEVCHSQTGQCE DAVNAKNCQPCRCNI NGS FSEICHTRTGQCE | IALTRGAEVKGRCGHSQSELQVFWVDRAYAL ISLTRGAEVKGHCGH NES ELEVFWVDHAYTL | ILKNEGFYSSTCPAESSTNTTQDEQRRWPGC MLKKEGFYSSLCPAE NRT NTTQDEQHQWTSC | NWGLLTFREETLLYDSNTSSMADRKLVTKII NWGLLTFREETLLYD NAT SSVADRKLVTKII | SVYVQLEKVCRGNPADVTEARLSFYSGHSSF SGYVQLE-VCRGSPA NVT EARLSFYSGHSSF | SLLLLVASQNKIIADSVTSQVHNIYSLVENG NLLLVVASRDKIIMD NIT AHTHNIYSLVQDV | CLDASDEADCPTRFPDGAYCQATMFECKNHV CLDASDESACPTRF P NGT YCPAAMFECKNHV | THPLGNFSFSSQCAFSCSEGTNLTGIEETTC IHPLGNFSFQSKCAF NCS EGRELLGTAETQC | KNLDKLIRLVNAQQAKGSSVHVLYSTPACYL KNMDKLIRLVNAQQV NGS LVHVLYSTPTCYL | TLCGQESTDTERAPGKDTFYSLGSSLDITFR TLCGQESTDTEQAPG NDT FYSLGPSLKVTFH | DSCRGDSGGALVFLDSETERWFVGGIVSWGS DSCRGDSGGALVFLD NET QRWFVGGIVSWGS | QVTSVESKPLPPLAFKHTVGHIILSEHKGVK QVTSTASKLLPPVAF NHT IGHIVLSEHKNVK | FGVFAQSKPDSAEPMDRSAMCAFPIKYVNDF FGVFAQSKPDSAEPV NRS AVCAFPIKYVNDF |
| Position | 479 | 1337 1344 | 923 919 | 102 | 54 54 | 447 | 156 155 | 1450 1451 | 3838 3840 | 226 226 | 345 345 | 103 | 642 641 | 97 | 358 357 |
| UniProt ID | ITB5_HUMAN ITB5_MOUSE | LAMA1_HUMAN LAMA1_MOUSE | LAMA2_HUMAN LAMA2_MOUSE | LAMP5_HUMAN LAMP5_MOUSE | LAT3_HUMAN LAT3_MOUSE | LCAP_HUMAN LCAP_MOUSE | LPP2_HUMAN LPP2_MOUSE | LRP2_HUMAN LRP2_MOUSE | LRP2_HUMAN LRP2_MOUSE | LYAM1_HUMAN LYAM1_MOUSE | MA2B1_HUMAN MA2B1_MOUSE | MASP2_HUMAN MASP2_MOUSE | MASP2_HUMAN MASP2_MOUSE | MERTK_HUMAN MERTK_MOUSE | MET_HUMAN MET_MOUSE |
| No. | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |

Table I. Condinued.

| No. | UniProt ID | Position | Sequence ^a | Clade | Gene | Protein |
|-----|----------------------------|------------|---|------------------------|---------|---|
| | PTPRB_HUMAN PTPRB_MOUSE | 709 | VRECSFSSLTPGRLYTVTITTRSGKYENHSF VSECSFSSLTPGRLY NVT VTTKSGNYASHSF | Simians | PTPRB | Receptor-type tyrosine-protein phosphatase β |
| | PTPRF_HUMAN PTPRF_MOUSE | 950 941 | AWDPPVLAERNGRIISYTVVFRDINSQQELQ TWDPPVLAERNGHIT NYT VVYRDINSQLELQ | Simians | PTPRF | Receptor-type tyrosine-protein phosphatase F |
| | SIAT9_HUMAN SIAT9_MOUSE | 280 | LFKSVDFNWLQAMVKKETLPFWVRLFFWKQV LFKSVDFKWLQAMVK NES LPFWVRLFFWKQV | Humans | ST3GAL5 | Lactosylceramide α -2,3-sialyltransferase |
| | ST14_HUMAN ST14_MOUSE | 489 | WADCTDHSDELNCSCDAGHQFTCKNKFCKPL WADCPDYSDERYCRC NAT HQFTCKNQFCKPL | Catarrhines | ST14 | Suppressor of tumorigenicity 14 protein |
| | STAB2_HUMAN STAB2_MOUSE | 63 | LNLGVKCPDGYTMITSGSVGVRDCRYTFEVR VNIAVKCPDGYIKIT NGT VGVRDCRYSLKIQ | Apes | STAB2 | Stabilin-2 |
| | SUSD2_HUMAN SUSD2_MOUSE | 703 | FCNFDVAATGSLSTGTATRVAHQLHQRRMQS FCILDVMSTGSSSVG NAT RIAHQLHQHRLKS | African great apes | SUSD2 | Sushi domain-containing protein 2 |
| | TMM62_HUMAN TMM62_MOUSE | 384 384 | SGPIFVLKWNPRNYSSGTHNIEVIVQDSAGR SGPIFILKWNPRNYS NGT HTIEVFVQDSAGR | Simians | TMEM62 | Transmembrane protein 62 |
| | VGFR3_HUMAN VGFR3_MOUSE | 582 582 | ELLEGQPVLLSCQADSYKYEHLRWYRLNLST DPLEGQSVRLSCRAD NYT YEHLRWYRLNLST | Simians | FLT4 | Vascular endothelial growth factor receptor 3 |
| | VNN1_HUMAN VNN1_MOUSE | 146 148 | NSIYVVANIGDKKPCDTSDPQCPPDGRYQYN NSIYVVANMGDKKPC NTS DSHCPPDGRFQYN | Humans and chimpanzees | VNNI | Pantetheinase |
| | VSII0_HUMAN VSII0_MOUSE | 100 | ATSLHIESLSLGDEGIYTCQEILNVTQWFQV AGALRIEALRLEDDG NYT CQEVLNETHWFPV | Humans | 01SISA | V-set and immunoglobulin domain-containing protein 10 |

^aThe N-glycosylation motif. Bold, N-X-S/T in mouse protein.




Figure 2. Timing of loss of ancestral N-glycosylation sites in the human lineage. The number of lost ancestral N-glycosylation sites is shown on the branch of each corresponding clade.

sites that have been lost in each common ancestor along the human lineage: humans, three; humans and chimpanzees, two; African great apes, six; great apes, one; apes, two; catarrhines, three; simians, 19; primates, three; and Euarchonta, one.

Of the 37 N-glycosylation sites that were lost in the human lineage since the divergence of the Euarchonta and the Glires, three events occurred in human proteins after the divergence of humans and chimpanzees (Table I, nos. 7, 33 and 40 and Fig. 3). The residue positions for these human-specific losses are Ser-2140 in cadherin EGF LAG seven-pass G-type receptor 1 encoded by the *CELSR1* gene, Lys-280 in lactosylceramide α -2,3-sialyltransferase encoded by the *ST3GAL5* gene, and Ile-100 in the V-set and immunoglobulin domain-containing protein 10 encoded by the *VSIG10* gene.

Human-specific loss of N-glycosylation at the amino acid position 2140 of CELSR1. The human cadherin EGF LAG seven-pass G-type receptor 1 or CELSR1, encoded by the CELSR1 gene, is a heavily glycosylated protein with 20 glycosylation sites (http://www.uniprot.org/uniprot/Q9NYQ6). Sequence comparison revealed that an ancestrally conserved glycosylation site at position 2140 was altered from Asn to Ser in humans following the human-chimpanzee divergence (Fig. 3A). The other mammals examined have a conserved Asn residue, conforming to the N-glycosylation motif consensus.

The CELSR1 protein is a member of the flamingo cadherin protein family, which are proteins located at the plasma membrane with seven transmembrane domains (16,17). It has nine cadherin domains, seven epidermal growth factor-like repeats and two laminin A G-type repeats. This gene is highly expressed during mouse embryonic development, especially in the central nervous system (16,17). Mutations in this protein were reported to cause neural tube defects and caudal agenesis

in humans (18,19). Therefore, CELSR1 may play an important role in contact-mediated signaling during nervous system formation in early embryogenesis. CELSR1 also plays an important role in the development of other organs, such as lung branching morphogenesis (20), intraluminal valve formation in lymphatic vessels (21), and hair follicle polarization and orientation (22).

Therefore, changes in the CELSR1 protein may be involved in the evolution of the nervous system, lung, lymphatic system, or hair patterns. However, a probable direct phenotypic consequence of the loss of the N-glycosylation site at position 2140 in humans remains to be determined.

Human-specific loss of N-glycosylation at the amino acid position 280 of ST3GAL5. The human lactosylceramide α-2,3-sialyltransferase, encoded by the ST3GAL5 gene, which is also known as ganglioside GM3 synthase or sialyltransferase 9 (SIAT9), has three N-glycosylation sites (http://www.uniprot. org/uniprot/Q9UNP4). A sequence comparison revealed that the human protein lost a conserved N-glycosylation site at 280 (Asn to Lys) following the human-chimpanzee divergence (Fig. 3B). All of the other mammals analyzed, except three, have the N-glycosylation consensus sequence at this site. A loss of the N-glycosylation consensus motif was also identified in guinea pigs, chinchillas, and brush-tailed rats (also known as degus), which have a Gly residue instead of Asn at the corresponding position. The three species belong to the rodent clade Caviomorpha (23), suggesting that the Asn-to-Gly change occurred in an ancestor of the three mammals.

The *ST3GAL5* gene encodes a sialyltransferase, a type II membrane protein that catalyzes the formation of GM3, a glycosphingolipid enriched in neural tissue, by adding sialic acid to lactosylceramide (24,25). GM3 is known to participate




Figure 3. Human-specific losses of ancestral N-glycosylation sites. The ancestral N-glycosylation sites and the surrounding regions of (A) CELSR1 Ser-2140, (B) ST3GAL5 Lys-280 and (C) VSIG10 Ile-100 are presented. The ancestral N-glycosylation consensus sequences are highlighted in grey, and corresponding sequences that lost the consensus, in black. The adjacent conserved N-glycosylation site Asn-108 in VSIG10 is indicated by plus signs (+++). The residues that are identical to those in the human sequence are indicated by dots (.). Dashes (-) denote alignment gaps. In some species, the sequences were not determined. hum, humans; hac, humans and chimpanzees; aga, African great apes; gra, great apes; ape, apes; cat, catarrhines; sim, simians; pri, primates; eua, Euarchonta; gli, Glires; lau, Laurasiatheria; afr, Afrotheria; xen, Xenarthra; mar, Marsupialia; and mon, Monotremata.

in the induction of cell differentiation, modulation of cell proliferation, and integrin-mediated cell adhesion.

Mutations in this gene are associated with several neurological disorders, such as Amish infantile epilepsy syndrome (26), Salt and Pepper syndrome characterized by severe intellectual disability, epilepsy, scoliosis, choreoathetosis, dysmorphic facial features and altered dermal pigmentation (25), or disruption of the structural integrity and function of cochlear hair cells (27). Therefore, the ST3GAL5 enzyme is crucial for normal neural development and function. The loss of an ancestrally conserved N-glycosylation site may be associated with a novel phenotype in the nervous system and function in humans, which may be demonstrated by molecular functional analysis.

Human-specific loss of N-glycosylation at position 100 of VSIG10. The VSIG10 gene encodes for V-set and immunoglobulin domain-containing protein 10. The human VSIG10 protein has nine N-glycosylation sites (http://www.uniprot.org/uniprot/Q8N0Z9). In the present study, we found that this protein lost an ancestrally conserved site at position 121, specifically, an Asn-to-Ile mutation abolished the N-glycosylation consensus (Fig. 3C). Of note, the consensus motif was also independently lost in squirrels and chinchillas. VSIG10 is a single-pass type I membrane protein containing a V-set domain, two immunoglobulin domains, and an I-set domain, which is present in cell adhesion molecules. No known molecular or biological function of VSIG10 has been reported.

In conclusion, we have identified 40 cases for loss of ancestrally conserved N-glycosylation sites, three of which are human-specific. Two human-specific losses occurred in the CELSR1 and ST3GAL5 proteins, which play indispensable roles in the normal development and function of the nervous systems. This finding suggests that the loss of N-glycosylation sites in these proteins may be associated with the evolution of human cognitive function. We suggest that a loss of ancestrally conserved N-glycosylation sites may result in the evolution of novel phenotypes, and the cases identified in the present study may serve as immediate targets for functional analyses to elucidate the molecular basis for an explanation of human phenotype evolution.

Acknowledgements

This study was supported by the National Research Foundation of Korea (NRF) grant (NRF-2012R1A1B3001513) funded by the Ministry of Education, Science and Technology, Republic of Korea.

References

- 1. Schwarz F and Aebi M: Mechanisms and principles of N-linked protein glycosylation. Curr Opin Struct Biol 21: 576-582, 2011. 2. Helenius A and Aebi M: Intracellular functions of N-linked
- glycans. Science 291: 2364-2369, 2001.

 3. Dennis JW, Nabi IR and Demetriou M: Metabolism, cell surface
- organization, and disease. Cell 139: 1229-1241, 2009.
- 4. Scott H and Panin VM: The role of protein N-glycosylation in neural transmission. Glycobiology 24: 407-417, 2014.
- 5. Park C and Zhang J: Genome-wide evolutionary conservation of N-glycosylation sites. Mol Biol Evol 28: 2351-2357, 2011.
- 6. Winterpacht A, Hilbert K, Stelzer C, Schweikardt T, Decker H, Segerer H, Spranger J and Zabel B: A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochon-
- droplasia. Physiol Genomics 2: 9-12, 2000.

 7. Wujek P, Kida E, Walus M, Wisniewski KE and Golabek AA: N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I. J Biol Chem 279: 12827-12839,
- 8. Mazumder R, Morampudi KS, Motwani M, Vasudevan S and Goldman R: Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes. PLoS One 7: e36212, 2012.
- 9. Deng L, Song J, Gao X, Wang J, Yu H, Chen X, Varki N, Naito-Matsui Y, Galán JE and Varki A: Host adaptation of a bacterial toxin from the human pathogen Salmonella Typhi. Cell 159: 1290-1299, 2014
- 10. Rich SM, Leendertz FH, Xu G, LeBreton M, Djoko CF, Aminake MN, Takang EE, Diffo JL, Pike BL, Rosenthal BM, et al: The origin of malignant malaria. Proc Natl Acad Sci USA 106: 14902-14907, 2009.
- 11. Zielinska DF, Gnad F, Wiśniewski JR and Mann M: Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell 141: 897-907, 2010.

- 12. Kim DS and Hahn Y: The acquisition of novel N-glycosylation sites in conserved proteins during human evolution. BMC Bioinformatics 16: 29, 2015.
- Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AF, Roskin KM, Baertsch R, Rosenbloom K, Clawson H, Green ED, et al: Aligning multiple genomic sequences with the threaded blockset aligner. Genome Res 14: 708-715, 2004.
- 14. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D and Kent WJ: The UCSC Table Browser data retrieval tool. Nucleic Acids Res 32: D493-D496, 2004.
- 15. Edgar RC: MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32: 1792-1797,
- 16. Hadjantonakis AK, Sheward WJ, Harmar AJ, de Galan L, Hoovers JM and Little PF: Celsrl, a neural-specific gene encoding an unusual seven-pass transmembrane receptor, maps to mouse chromosome 15 and human chromosome 22qter. Genomics 45: 97-104 1997
- 17. Hadjantonakis AK, Formstone CJ and Little PF: mCelsr1 is an evolutionarily conserved seven-pass transmembrane receptor and is expressed during mouse embryonic development. Mech Dev 78: 91-95, 1998.
- 18. Allache R, De Marco P, Merello E, Capra V and Kibar Z: Role of the planar cell polarity gene CELSR1 in neural tube defects and caudal agenesis. Birth Defects Res A Clin Mol Teratol 94: 176-181, 2012
- 19. Lei Y, Zhu H, Yang W, Ross ME, Shaw GM and Finnell RH: Identification of novel CELSR1 mutations in spina bifida. PLoS One 9: e92207, 2014.
- 20. Yates LL, Schnatwinkel C, Murdoch JN, Bogani D, Formstone CJ, Townsend S, Greenfield A, Niswander LA and Dean CH: The PCP genes Celsr1 and Vangl2 are required for normal lung branching morphogenesis. Hum Mol Genet 19: 2251-2267, 2010.
- 21. Tatin F, Taddei A, Weston A, Fuchs E, Devenport D, Tissir F and Makinen T: Planar cell polarity protein Ĉelsr1 regulates endothelial adherens junctions and directed cell rearrangements during valve morphogenesis. Dev Cell 26: 31-44, 2013.
- 22. Devenport D and Fuchs E: Planar polarization in embryonic epidermis orchestrates global asymmetric morphogenesis of hair follicles. Nat Cell Biol 10: 1257-1268, 2008.
- 23. Upham NS and Patterson BD: Diversification and biogeography of the Neotropical caviomorph lineage Octodontoidea (Rodentia: Hystricognathi). Mol Phylogenet Evol 63: 417-429, 2012. 24. Ishii A, Ohta M, Watanabe Y, Matsuda K, Ishiyama K, Sakoe K,
- Nakamura M, Inokuchi J, Sanai Y and Saito M: Expression cloning and functional characterization of human cDNA for ganglioside GM3 synthase. J Biol Chem 273: 31652-31655, 1998.
- 25. Boccuto L, Aoki K, Flanagan-Steet H, Chen CF, Fan X, Bartel F, Petukh M, Pittman A, Saul R, Chaubey A, et al: A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt and pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation. Hum Mol Genet 23: 418-433, 2014.
- 26. Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, Reinkensmeier G, Wang H, Wiznitzer M, Gurtz K, Verganelaki A, et al: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet 36: 1225-1229, 2004.
- 27. Yoshikawa M, Go S, Suzuki S, Suzuki A, Katori Y, Morlet T, Gottlieb SM, Fujiwara M, Iwasaki K, Strauss KA, et al: Ganglioside GM3 is essential for the structural integrity and function of cochlear hair cells. Hum Mol Genet 24: 2796-2807,